Recruiting
Renal transplant
RecruitingSafety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Registered drug
Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Registered drug
- Disease:Renal transplant
- Substances:Siplizumab
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Siplizumab
- Sponsor:Nefro Avillion Clinical Development LLC




